Rare Disease Pharmaceutical Service Market Growth Trends: Moderate Expansion with 13% CAGR Until 2029

 Get 30% Off All Market Studies With Code ONLINE30 — Anticipate Tariff Impacts, Market Disruptors, and Long-Term Growth Trends

 

 What Is the Expected Market Growth Rate for the Rare Disease Pharmaceutical Service Market?
 The rare disease pharmaceutical service market size has grown rapidly in recent years. It will grow from $117.70 billion in 2024 to $133.40 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to increasing focus on genetic research, rising adoption of advanced diagnostics, a growing number of patient registries, increasing collaborations between pharma and biotech, and rising awareness of orphan drug incentives.
 
 The rare disease pharmaceutical service market size is expected to see rapid growth in the next few years. It will grow to $217.37 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to increasing integration of AI in drug discovery, rising demand for personalized treatment plans, growing investment in rare disease clinical trials, increasing use of real-world evidence in decision-making, and rising regulatory support for rare disease therapies. Major trends in the forecast period include advancements in AI-powered drug discovery, integration of digital health platforms, technology-enabled patient monitoring, developments in biomarker-driven therapies, and advancements in decentralized clinical trials.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28314&type=smp
 
 Which Major Growth Factors Are Shaping the Rare Disease Pharmaceutical Service Market?
 The rise of personalized medicine is expected to propel the growth of the rare disease pharmaceutical service market going forward. Personalized medicine is an approach that tailors medical treatment to a patient’s genetic profile, lifestyle, and environment for more effective and precise care. The rise of personalized medicine is driven by advances in genomics, biomarker research, and data analytics, which allow treatments to be tailored to an individual’s genetic profile, improving effectiveness, reducing side effects, and addressing unmet patient needs more precisely than traditional one-size-fits-all therapies. Pharmaceutical Service supports personalized medicine by developing targeted therapies, leveraging genetic and biomarker data, and providing tailored treatment solutions to meet the unique needs of individual patients. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, compared to 6 approvals in 2022. Therefore, the rise of personalized medicine is driving the growth of the rare disease pharmaceutical service market.
 
 What Are the Emerging Segments in the Rare Disease Pharmaceutical Service Market?
 The rare disease pharmaceutical service market covered in this report is segmented as
 
 1) By Types: Drug Discovery, Clinical Trials, Other Types
 2) By Application: Congenital And Genetic Diseases, Tumors And Cancer, Endocrine Diseases
 3) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutions, Hospitals And Specialty Clinics, Contract Research Organizations (CROs) And Contract Development And Manufacturing Organizations (CDMOs), Diagnostic Laboratories And Genetic Testing Centers
 
 Subsegments:
 1) By Drug Discovery: Target Identification And Validation, Preclinical Research And Toxicology Studies, Biomarker Discovery And Validation, Genomic And Proteomic Analysis, Computational Drug Design And Modeling, High-Throughput Screening (HTS), Lead Optimization And Candidate Selection
 2) By Clinical Trials: Clinical Trial Design And Protocol Development, Patient Recruitment And Retention, Site Management And Monitoring, Regulatory Affairs And Compliance Support, Data Management And Biostatistics, Pharmacovigilance And Safety Monitoring, Real-World Evidence (RWE) And Post-Marketing Studies
 3) By Other Types: Market Access And Pricing Strategy, Health Economics And Outcomes Research (HEOR), Regulatory Affairs And Compliance Services, Manufacturing And CMC (Chemistry, Manufacturing, and Controls) Support, Medical Affairs And Scientific Communication, Post-Marketing Surveillance, Consulting And Strategic Advisory
 
 What Are the Future Trends Forecasted for the Rare Disease Pharmaceutical Service Market?
 Major companies operating in the rare disease pharmaceutical service market are increasingly focusing on developing novel treatment approaches, such as acetylleucine, to improve treatment effectiveness, enhance patient outcomes, and address unmet needs in rare neurological and metabolic disorders. Acetylleucine, a modified amino acid (N-acetyl-L-leucine), is used as a therapeutic agent to support motor function, balance, and neurological health in affected patients. For instance, in September 2024, IntraBio, a US-based biopharmaceutical firm, received FDA approval for AQNEURSA, the first stand-alone therapy for Niemann-Pick Disease Type C, a rare, life-threatening neurodegenerative disorder. This milestone is significant, as the treatment demonstrated rapid and meaningful improvements in neurological symptoms, offering a groundbreaking therapeutic option for both pediatric and adult patients living with this rare disease.
 
 Which Companies Hold the Largest Share in the Rare Disease Pharmaceutical Service Market?
 Major companies operating in the rare disease pharmaceutical service market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Chiesi Farmaceutici S.p.A., Recordati Industria Chimica e Farmaceutica S.p.A., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Travere Therapeutics Inc., Sciensus Healthcare Ltd., and SOM Innovation Biotech S.L.
 
 Get the full rare disease pharmaceutical service market report here:
 https://www.thebusinessresearchcompany.com/report/rare-disease-pharmaceutical-service-global-market-report
 
 Which Regions Are Driving the Most Demand in the Rare Disease Pharmaceutical Service Market?
 North America was the largest region in the rare disease pharmaceutical service market in 2024. The regions covered in rare disease pharmaceutical service report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company